Hyperuricemia and the Echocardiographic Measures of Myocardial Dysfunction

Congestive Heart Failure

Volumn 18, Issue 3, 2012, Pages 138-143

  Krishnan, Eswar ^a   Hariri, Ali ^b   Dabbous, Omar ^b   Pandya, Bhavik J ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Takeda Pharmaceuticals International Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ADULT; ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART LEFT VENTRICLE WALL; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RISK FACTOR; URIC ACID BLOOD LEVEL;

COHORT STUDIES; ECHOCARDIOGRAPHY; FEMALE; HEART FAILURE; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; HYPERURICEMIA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; URIC ACID; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84861192064     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00259.x     Document Type: Article

References (48)

1. Hunt SA, Abraham WT, Chin MH, et al; American College of Cardiology Foundation, American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53:e1-e90.
2. Schocken DD, Benjamin EJ, Fonarow GC, et al; American Heart Association Council on Epidemiology and Prevention, American Heart Association Council on Clinical Cardiology, American Heart Association Council on Cardiovascular Nursing, American Heart Association Council on High Blood Pressure Research, Quality of Care and OutcomesResearch Interdisciplinary Working Group, Functional Genomics and Translational Biology Interdisciplinary Working Group. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research InterdisciplinaryWorking Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544-2565.
3. Bibbins-Domingo K, Pletcher MJ, Lin F, et al. Racial differences in incident heart failureamong young adults. N Engl J Med 2009;360:1179-1190.
4. Thomas RD, Newill A, Morgan DB. The cause of the raised plasma urea of acute heart failure. Postgrad Med J 1979;55:10-14.
5. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J. 1997;18:858-865.
6. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J. 1999;13:682-685.
7. Mitsuhashi H, Yatsuya H, Matsushita K, et al. Uric acid and left ventricular hypertrophy in Japanese men. Circ J. 2009;73:667-672.
8. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J. 1998;19:1814-1822.
9. Olexa P, Olexová M, Gonsorcík J, et al. Uric acid--a marker for systemic inflammatory response in patients with congestive heart failure? Wien Klin Wochenschr. 2002;114:211-215.
10. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation andapplication in metabolic, functional, and hemodynamic staging. Circulation. 2003;107:1991-1997.
11. Hare JM, Johnson RJ. Uric acid predicts clinical outcomes in heart failure: insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation. 2003;107:1951-1953.
12. Kojima S, Sakamoto T, Ishihara M, et al; Japanese Acute Coronary Syndrome Study (JACSS) Investigators. Prognostic usefulness of serum uric acid after acute myocardial infarction (the Japanese Acute Coronary Syndrome Study). Am J Cardiol. 2005;96:489-495.
13. Niizeki T, Takeishi Y, Arimoto T, et al. Hyperuricemia associated with high cardiac event rates in the elderly with chronic heart failure. J Cardiol. 2006;47:219-228.
14. Doehner W, von Haehling S, Anker SD. Uric acid as a prognostic marker in acute heart failure--new expectations from an old molecule. Eur J Heart Fail. 2007;9:437-439.
15. Kittleson MM, St John ME, Bead V, et al. Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart. 2007;93:365-367.
16. Pascual-Figal DA, Hurtado-Martínez JA, Redondo B, et al. Hyperuricaemia and long-term outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail. 2007;9:518-524.
17. Krishnan E. Hyperuricemia and incident heart failure. Circ Heart Fail. 2009;2:556-562.
18. Kannel WB, Feinleib M, McNamara PM, et al. An investigation of coronary heart disease in families. The Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
19. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23:1835-1839.
20. Abbott RD, Brand FN, Kannel WB, Castelli WP. Gout and coronary heart disease: the Framingham Study. J Clin Epidemiol. 1988;41:237-242.
21. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-1562.
22. Lee DS, Pencina MJ, Benjamin EJ, et al. Association of parental heart failure with risk of heart failure in offspring. N Engl J Med. 2006;355:138-147.
23. Vasan RS, Benjamin EJ, Larson MG, et al Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA. 2002;288:1252-1259.
24. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083.
25. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
26. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2001;37:1042-1048.
27. Wang TJ, Evans JC, Benjamin EJ, et al. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation. 2003;108:977-982.
28. Lloyd-Jones DM, Larson MG, Leip EP, et al.; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106:3068-3072.
29. American Heart Association. Heart Disease and Stroke Statistics - 2010 Update. Dallas, Texas: American Heart Association; 2010.
30. Page RL, Strongin KB, Mills RM, et al. The magnitude of health care resource utilization by Medicare beneficiaries with heart failure. Circulation. 2007;116:II-600. Abstract 2707.
31. Writing group members, Lloyd-Jones D, Adams RJ, et al. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010;121:e46-e215.
32. Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol. 2005;16:3553-3562.
33. Sundström J, Sullivan L, D'Agostino RB, et al. Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension. 2005;45:28-33.
34. Cowan BR, Young AA. Left ventricular hypertrophy and renin-angiotensin system blockade. Curr Hypertens Rep. 2009;11:167-172.
35. Cardillo C, Kilcoyne CM, Cannon RO 3rd, et al. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997;30:57-63.
36. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension. 2000;35:746-751.
37. Farquharson CA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation. 2002;106:221-226.
38. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 2002;105:2619-2624.
39. Kao MP, Ang DS, Gandy SJ, et al. Allopurinol Reduces Both Left Ventricular Hypertrophy and Endothelial Dysfunction in Patients with Chronic Kidney Disease. June 25-28, Munich, Germany: XLVII European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Congress; 2010. Abstract OSu068.
40. George J, Carr E, Davies J, et al. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation. 2006;114:2508-2516.
41. Xu X, Hu X, Lu Z, et al. Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail. 2008;14:746-753.
42. Antony R, Dargie HJ. Allopurinol for chronic stable angina: old drug, new tricks? Lancet. 2010;375:2126-2127.
43. Ogino K, Kato M, Furuse Y, et al. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study. Circ Heart Fail. 2010;3:73-81.
44. Hare JM, Mangal B, Brown J, et al; OPT-CHF Investigators. Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol. 2008;51:2301-2309.
45. Thanassoulis G, Brophy JM, Richard H, Pilote L. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med. 2010;170:1358-1364.
46. Struthers AD, Donnan PT, Lindsay P, et al. Effect of allopurinol on mortality and hospitalisations in chronic heart failure: a retrospective cohort study. Heart. 2002;87:229-234.
47. Wei L, Fahey T, Struthers AD, MacDonald TM. Association between allopurinol and mortality in heart failure patients: a long-term follow-up study. Int J Clin Pract. 2009;63:1327-1333.
48. Cingolani HE, Plastino JA, Escudero EM, et al. The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail. 2006;12:491-498.